A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer

Koto, Masashi; Takai, Yoshihiro; Ogawa, Yoshihiro; Matsushita, Haruo; Takeda, Ken; Takahashi, Chiaki; Britton, K.; Jingu, K.; Takai, Kenji; Mitsuya, Masatoshi; Nemoto, Kenji; Yamada, Satoshi

doi:10.1016/j.radonc.2007.10.017

Cited by 161 publications

(97 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison with photons, PBT plans may deliver lower doses to the adjacent organs at risk, such as the esophagus, lungs and bone marrow, thus improving the therapeutic ratio (15). The early clinical outcome of PBT in lung cancer patients (16)(17)(18)(19)(20)(21)(22)(23) demonstrated that proton beam therapy combined with chemotherapy may relatively reduce the rates of toxicity and achieve a possible survival benefit compared with photon beam therapy and 3DCRT (24). Early results (25)(26)(27)(28)(29) suggested that PBT has the advantage of dose escalation, which may prolong patient survival, lower the risk of recurrence and severe toxicity, and intensify chemotherapy (15).…”

Section: Pbt For Different Cancersmentioning

confidence: 99%

The evolution of proton beam therapy: Current and future status (Review)

et al. 2017

View full text Add to dashboard Cite

Abstract. Proton beam therapy (PBT) has been increasingly used in a variety of cancers due to its excellent physical properties and superior dosimetric parameters. PBT may improve patient survival by improving the local tumor treatment rate while reducing injury to normal organs, which may result in fewer radiation-induced adverse effects. However, the significant cost of establishing and maintaining proton facilities cannot be overlooked. In addition, there has been significant controversy regarding routine application of this treatment in certain types of cancer. The challenges of PBT in the future mainly include the lack of basic clinical trials, unclear biological effects, immature imaging technology and miniaturization of imaging guidance. Overcoming these limitations may promote the rapid development of PBT. We herein provide an overview of the existing literature on the efficacy and toxicity of common oncological applications of proton beam therapy.

show abstract

Section: Pbt For Different Cancersmentioning

confidence: 99%

The evolution of proton beam therapy: Current and future status (Review)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Stereotactic Ablative Radiotherapy (SABR) or Stereotactic Body Radiotherapy (SBRT) currently represents a standard of care forinoperable stage I NSCLC, offering a survival advantage overtraditional radiotherapy and cancer-specific survival rates compa-rable to surgical series in retrospective and prospective studies [1][2][3][4][5][6]. Histological confirmation of lung nodules prior to SABRhas been a concern since the introduction of this treatment, bothin clinical studies and in daily practice.…”

Section: Introductionmentioning

confidence: 99%

Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study

et al. 2014

View full text Add to dashboard Cite

“…Stereotactic body radiation therapy (SBRT) is emerging as an efficient treatment for Stage I/ II medical inoperable and surgically unresectable non-small-cell and metastatic lung cancer [1][2][3][4][5][6][7][8][9][10][11][12]. Dose escalation and hypofractional dose delivery has the potential to increase patients' survival rates [3] and the probability of local tumor control [4,6,8], while increasing median survival time and long-term progression-free survival [7].…”

Section: Introductionmentioning

confidence: 99%

An evaluation of planning techniques for stereotactic body radiation therapy in lung tumors

Shekhar

et al. 2008

Radiotherapy and Oncology

View full text Add to dashboard Cite

Purpose-To evaluate four planning techniques for stereotactic body radiation therapy (SBRT) in lung tumors.Methods and Materials-Four SBRT plans were performed for 12 patients with stage I/II nonsmall-cell lung cancer under the following conditions: (1) conventional margins on free-breathing CT (plan 1), (2) generation of an internal target volume (ITV) using 4DCT with beam delivery under free-breathing conditions (plan 2), (3) gating at end-exhale (plan 3), and (4) gating at end-inhale (plan 4). Planning was performed following the RTOG 0236 protocol with a prescription dose of 54Gy (3 fractions). For each plan 4D dose was calculated using deformable image registration.Results-There was no significant difference in tumor dose delivered by the 4 plans. However, compared with plan 1, plans 2-4 reduced total lung BED by 1.9±1.2Gy, 3.1±1.6Gy and 3.5±2.1Gy, reduced mean lung dose by 0.8±0.5Gy, 1.5±0.8Gy, and 1.6±1.0Gy, reduced V20 by 1.5±1.0%, 2.7 ±1.4%, and 2.8±1.8% respectively with p<0.01. Compared with plan 2, plans 3-4 reduced lung BED by 1.2±1.0Gy and 1.6±1.5Gy, reduced mean lung dose by 0.6±0.5Gy and 0.8±0.7Gy, reduced V20 by 1.2±1.1% and 1.3±1.5% respectively with p<0.01. The differences in lung BED, mean dose and V20 of plan 4 compared with plan 3 are insignificant.Conclusions-Tumor dose coverage was statistically insignificant between all plans. However, compared with plan 1, plans 2-4 significantly reduced lung doses. Compared with plan 2, plan 3-4 also reduced lung toxicity. The difference in lung doses between plan 3 and plan 4 was not significant.

show abstract

A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer

Cited by 161 publications

References 29 publications

The evolution of proton beam therapy: Current and future status (Review)

The evolution of proton beam therapy: Current and future status (Review)

Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study

An evaluation of planning techniques for stereotactic body radiation therapy in lung tumors

Contact Info

Product

Resources

About